Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Dec 1;150(12):1078-1086.
doi: 10.1001/jamaoto.2024.2556.

Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake

Affiliations
Comment

Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake

Michael F Armstrong et al. JAMA Otolaryngol Head Neck Surg. .

Abstract

Importance: Asymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.

Objective: To identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.

Design, setting, and participants: In this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.

Exposure: Blinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.

Main outcomes and measures: The primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.

Results: Of the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).

Conclusions and relevance: In this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Burkett reported grants from GE HealthCare and Radiological Society of North America outside the submitted work. Dr D. Price reported royalties from InSitu Biologics and is a consultant for Medivis outside the submitted work. Dr Lester reported royalties from Empyrean Medical outside the submitted work. Dr Lowe reported nonfinancial support from AVID Radiopharmaceuticals, grants from Siemens Healthcare, and personal fees from Eli Lilly outside the submitted work. Dr Van Abel reported consulting fees from Intuitive Surgical and has an intellectual property submitted to Exact Sciences outside the submitted work. No other disclosures were reported.

Comment in

Comment on

Similar articles

Cited by

References

    1. Fonti R, Conson M, Del Vecchio S. PET/CT in radiation oncology. Semin Oncol. 2019;46(3):202-209. doi:10.1053/j.seminoncol.2019.07.001 - DOI - PubMed
    1. Slevin NJ, Collins CD, Hastings DL, et al. . The diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer. J Laryngol Otol. 1999;113(6):548-554. doi:10.1017/S0022215100144457 - DOI - PubMed
    1. Oshida M, Uno K, Suzuki M, et al. . Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998;82(11):2227-2234. doi:10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO;2-W - DOI - PubMed
    1. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. ; Leuven Lung Cancer Group . Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999;17(10):3201-3206. doi:10.1200/JCO.1999.17.10.3201 - DOI - PubMed
    1. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26(4):308-314. doi:10.1016/S0001-2998(96)80006-7 - DOI - PubMed

LinkOut - more resources